Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

IEI trades at $113.465 with minimal daily movement (+0.07%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces resistance at $114 with support at $113. Recent dividend payments of $0.37-0.38 demonstrate consistent shareholder returns, though key financial ratios remain unavailable for fundamental assessment.

The bearish technical outlook and lack of fundamental data create uncertainty. Bond market volatility and rising Treasury yields present macroeconomic headwinds. Investment potential depends on forthcoming financial disclosures and the company's ability to navigate current interest rate environment.